These are the upcoming stock splits for the week of October 20 to October 24, based on TipRanks’ Stock Splits Calendar. A stock split doesn’t magically make a company worth more, but it does change how it looks. The number of shares increases, the price per share drops, and suddenly the stock feels more “within reach” for everyday investors. Same value, different psychology – and sometimes, that’s all it takes to spark new interest.
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
A reverse stock split is the opposite play. Fewer shares, higher price, same market value. Companies usually pull this move to stay compliant with exchange rules – like Nasdaq’s minimum share price – and prevent a potential delisting.
Whether the goal is to attract attention or avoid getting kicked off the stage, these moves aren’t just administrative – they’re signals, and the market watches them closely.
Let’s take a look at the upcoming stock splits for the week.
Senseonics Holdings (SENS) – Senseonics is a medical technology company best known for developing long-term implantable continuous glucose monitoring (CGM) systems for people with diabetes. Its flagship Eversense platform uses a small sensor implanted under the skin, paired with a wearable transmitter and mobile app to provide real-time glucose readings, alerts, and trend data for months at a time – significantly longer than traditional CGMs. On October 16, the company announced a 1-for-20 reverse stock split, primarily to bring its share price back into compliance with the New York Stock Exchange’s minimum bid-price requirements; the split is set to take effect on October 20.
ETHZilla Corporation (ETHZ) – ETHZilla, formerly known as 180 Life Sciences, has transitioned from its pharmaceutical roots into a digital asset and Web3-focused company. Today, it functions as an Ethereum-based treasury and technology platform, holding a reserve of Ether and aiming to generate returns through staking, restaking, and participation in blockchain infrastructure. The company also allocates capital to layer-2 networks and Ethereum ecosystem projects to build long-term value. On October 14, ETHZilla announced a 1-for-10 reverse stock split, effective when markets open on October 20, aiming to consolidate its share structure, increase its share price, and ensure continued compliance with stock exchange listing standards.
Aethlon Medical (AEMD) – Aethlon Medical is a clinical-stage biotech and medical device company developing immunotherapeutic technologies for life-threatening infectious diseases and cancer. Its lead product, the Hemopurifier, is a first-in-class blood-filtration device designed to remove cancer-promoting exosomes and circulating viruses from the bloodstream. On October 14, the company announced a 1-for-10 reverse stock split to regain compliance with Nasdaq’s minimum bid-price requirement and preserve its listing status. The split became effective on October 16, with trading on a split-adjusted basis beginning October 20.
DIH Holding US (DHAI) – DIH Holding US is a global provider of robotic and virtual-reality rehabilitation technologies used in hospitals, clinics, and research centers. Its product lineup includes robotic exoskeletons for upper- and lower-limb therapy, gait training systems, and VR-based platforms designed to help patients recover mobility after neurological injuries such as stroke or spinal cord damage. On October 16, the company announced a 1-for-25 reverse stock split, effective at the market open on October 20, in order to bring its share price back into compliance with Nasdaq’s minimum bid-price requirement and maintain its listing.
WORK Medical Technology Group (WOK) – China-based WORK Medical Technology Group is a manufacturer and distributor of medical consumables and devices, operating through its Hangzhou-based subsidiary and exporting to roughly 30 countries across Asia, Africa, Europe, the Americas and Oceania. The company’s product portfolio includes Class I and II disposable and durable medical devices such as face masks, breathing circuits, anesthetic kits, laryngoscope blades, suction sets, artery compression tourniquets, and airway management tools. Amid challenges including revenues that have fallen and a share price persistently under the required threshold for continued listing, on October 16, the company announced a 1-for-100 reverse stock split, effective October 21, with the aim of raising its per-share price and regaining compliance with the minimum bid-price requirement.
Genprex (GNPX) – Genprex is a clinical-stage gene therapy company developing treatments for cancer and diabetes using its proprietary non-viral nanoparticle delivery system. Its lead candidate, Reqorsa, is being evaluated in combination with existing lung cancer therapies. On the diabetes side, the company is developing a gene-therapy program that delivers Pdx1 and MafA genes directly to the pancreas to restore or regenerate insulin-producing cells for type 1 and type 2 diabetes. On October 13, the company announced a 1-for-50 reverse stock split to regain compliance with Nasdaq’s minimum bid-price and shareholder equity requirements. The split will take effect on October 21.
To find more information about historical and upcoming stock splits, visit the TipRanks Stock Splits Calendar.